Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03230747 · ClinicalTrials.gov registry record · NA
SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation
A NA study of Mitral Regurgitation and Mitral Disease, sponsored by Edwards Lifesciences.
- Active
- Registry status
- NA
- Development phase
- 72
- Enrollment target
- 9
- Study locations
NCT03230747 is a NA study of Mitral Regurgitation and Mitral Disease that is active but no longer recruiting, run by Edwards Lifesciences. The registered enrollment target is 72 participants, below the 1,021-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 8 states.
The verdict
NCT03230747, a NA study of Mitral Regurgitation and Mitral Disease, is active but no longer recruiting, sponsored by Edwards Lifesciences.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.
Conditions Studied
Interventions
- DEVICE Edwards SAPIEN M3 System
Study Locations (9)
California
- Cedars-Sinai Medical Center Heart Institute - Los Angeles
- California Pacific Medical Center - San Francisco
Georgia
- Emory University - Atlanta
Illinois
- Evanston/ Northshore University - Evanston
Michigan
- Henry Ford Hospital - Detroit
Minnesota
- Mayo Clinic - Rochester
Utah
- Intermountain Medical Center - Murray
Virginia
- Sentara Cardiovascular Research Institution - Norfolk
British Columbia
- St. Paul's Hospital - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2027-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03230747
The ClinicalTrials.gov registry entry for NCT03230747 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,021-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target (93% lower). The listed sponsor is Edwards Lifesciences, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which Edwards SAPIEN M3 System is the first listed.
NCT03230747 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT03230747 about?
NCT03230747 is a clinical study titled "SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation". This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.
What is the current status of trial NCT03230747?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2017-09-14. Estimated completion is 2027-08.
What conditions does trial NCT03230747 study?
This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Disease.
What interventions are being tested in trial NCT03230747?
The interventions under investigation include: Edwards SAPIEN M3 System (DEVICE).
Who is sponsoring clinical trial NCT03230747?
This trial is sponsored by Edwards Lifesciences, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03230747 being conducted?
This trial has 9 study locations across California, Georgia, Illinois, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
RECRUITING · NA
-
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
RECRUITING · NA
-
EFS of the CardioMech MVRS
RECRUITING · NA
-
Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock
RECRUITING · NA
-
Cephea Early Feasibility Study
RECRUITING · NA
-
Evaluating Infrasonic Hemodynography
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.